Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3737)
All Articles published online
|
Mar 28, 2012 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, Christensen S, Pfaff R, Theilmeier A, Alshuth U, Mauss S. Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012; 18(12): 1339-1347 [PMID: 22493547 DOI: 10.3748/wjg.v18.i12.1339] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i12/1339.htm |
| Number | Citing Articles |
| 1 |
Marie Feillant, Caroline Jézéquel, Hortensia Lison, Aurélien Delluc, Florence Tanné, Antonia Le Gruyer, Zeineb Ben Ali, Isabelle Renard, Marianne Latournerie, Yves Deugnier, Armand Garioud, Jean-François Cadranel, Dominique Guyader, Michel Robaszkiewicz, Jean-Baptiste Nousbaum. Chronic hepatitis C. European Journal of Gastroenterology & Hepatology 2016; 28(2): 164 doi: 10.1097/MEG.0000000000000506
|
| 2 |
Liesl M. Hagan, Raymond F. Schinazi. Best strategies for global HCV eradication. Liver International 2013; 33(s1): 68 doi: 10.1111/liv.12063
|
| 3 |
Claus Niederau, Stefan Mauss, Andreas Schober, Albrecht Stoehr, Tim Zimmermann, Michael Waizmann, Gero Moog, Stefan Pape, Bernd Weber, Konrad Isernhagen, Petra Sandow, Bernd Bokemeyer, Ulrich Alshuth, Hermann Steffens, Dietrich Hüppe, Partha Mukhopadhyay. Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. PLoS ONE 2014; 9(9): e107592 doi: 10.1371/journal.pone.0107592
|
| 4 |
Massimo Puoti, Roberto Rossotti, Giovanna Travi, Claudia Panzeri, Marco Morreale, Erika Chiari, Giorgia Cocca, Maurizio Orso, Maria Cristina Moioli. Optimizing treatment in HIV/HCV coinfection. Digestive and Liver Disease 2013; 45: S355 doi: 10.1016/j.dld.2013.09.001
|
| 5 |
Clara Smilg Nicolás, Francisco Jesús Vera Méndez, Josefina Vega Cervantes, Antonio Moreno Hernández. Tratamiento de la hepatitis crónica por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana. Medicina Clínica 2015; 145(2): 88 doi: 10.1016/j.medcli.2014.06.001
|
| 6 |
Julie Hepworth, Tanya Bain, Mieke van Driel. Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review. International Journal for Equity in Health 2013; 12(1): 92 doi: 10.1186/1475-9276-12-92
|
| 7 |
Susie H. Park. A psychiatric pharmacist in a liver clinic managing treated patients with chronic hepatitis C viral infection. Mental Health Clinician 2014; 4(6): 266 doi: 10.9740/mhc.n207200
|
| 8 |
Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio. Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. European Journal of Public Health 2017; 27(5): 938 doi: 10.1093/eurpub/ckx025
|
| 9 |
Stuart J. Turner, Jack Brown, Joseph A. Paladino. Protease Inhibitors for Hepatitis C: Economic Implications. PharmacoEconomics 2013; 31(9): 739 doi: 10.1007/s40273-013-0073-2
|
| 10 |
N. A. Malinina, N. V. Mazurchik, O. I. Tarasova, P. P. Ogurtsov. ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?. Siberian journal of oncology 2019; 18(3): 90 doi: 10.21294/1814-4861-2019-18-3-90-96
|
| 11 |
Gina Gamal Naguib, Tari George Michael, Yehia Elshazly, Maha Magdy Wahdan, Aya Mostafa, Ossama Ashraf Ahmed, Hany Dabbous, Heba Ismail Saad Aly, Mohamed Kamal Shaker, Hosam Samir Elbaz, Magdy El-Serafy, Wahid Doss, Sherief Abd-Elsalam, Manal Hamdy El-Sayed. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. VirusDisease 2021; 32(3): 582 doi: 10.1007/s13337-021-00712-4
|
| 12 |
Raffaele Bruno, Giuseppe Cariti, Paola Nasta, Amedeo Capetti, Veronica Ravasio, Massimo Galli, Enzo Raise, Giulio Palmieri, Claudio Iannacone, Massimo Puoti. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon‐naïve patients with HIV/HCV genotype 2/3 co‐infection in Italy. Liver International 2015; 35(1): 120 doi: 10.1111/liv.12641
|
| 13 |
Christoph Sarrazin. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 2016; 64(2): 486 doi: 10.1016/j.jhep.2015.09.011
|
| 14 |
Ming-Lung Yu, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Jee-Fu Huang, Chung-Feng Huang, Meng-Hsuan Hsieh, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Wen-Yi Lin, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang. Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. Medicine 2015; 94(13): e690 doi: 10.1097/MD.0000000000000690
|
| 15 |
J. T. Stahmeyer, C. Krauth, F. Bert, H. Pfeiffer‐Vornkahl, U. Alshuth, D. Hüppe, S. Mauss, S. Rossol. Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial. Journal of Viral Hepatitis 2016; 23(2): 105 doi: 10.1111/jvh.12471
|
| 16 |
Stine Bordier Høj, Nanor Minoyan, Andreea Adelina Artenie, Jason Grebely, Julie Bruneau. The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. Canadian Liver Journal 2018; 1(2): 4 doi: 10.3138/canlivj.1.2.003
|
| 17 |
Clara Smilg Nicolás, Francisco Jesús Vera Méndez, Josefina Vega Cervantes, Antonio Moreno Hernández. Chronic hepatitis C treatment in human infection virus coinfected patients. Medicina Clínica (English Edition) 2015; 145(2): 88 doi: 10.1016/j.medcle.2014.06.008
|
| 18 |
Lucio Boglione, Chiara Simona Cardellino, Jessica Cusato, Amedeo De Nicolò, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. Infection, Genetics and Evolution 2017; 51: 167 doi: 10.1016/j.meegid.2017.03.014
|
| 19 |
Peter Buggisch, Hans Heiken, Stefan Mauss, Bernd Weber, Maria-Christina Jung, Herbert Görne, Renate Heyne, Holger Hinrichsen, Dennis Hidde, Bettina König, Ana Gabriela Pires dos Santos, Claus Niederau, Thomas Berg, Chen-Hua Liu. Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLOS ONE 2021; 16(5): e0250833 doi: 10.1371/journal.pone.0250833
|
| 20 |
Kyrre H. Toresen, Ivar Mjåland Salte, Steinar Skrede, Roy Miodini Nilsen, Rafael Alexander Leiva. Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic. Scandinavian Journal of Gastroenterology 2014; 49(4): 465 doi: 10.3109/00365521.2013.863965
|
| 21 |
Claudia Roeder, Sabine Jordan, Julian Schulze zur Wiesch, Heike Pfeiffer-Vornkahl, Dietrich Hueppe, Stefan Mauss, Elmar Zehnter, Sabine Stoll, Ulrich Alshuth, Ansgar W Lohse, Stefan Lueth. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World Journal of Gastroenterology 2014; 20(31): 10984-10993 doi: 10.3748/wjg.v20.i31.10984
|
| 22 |
Gyde Steffen, Ida Sperle, Siv Aina Leendertz, Navina Sarma, Sandra Beermann, Roma Thamm, Viviane Bremer, Ruth Zimmermann, Sandra Dudareva, Isabelle Chemin. The epidemiology of Hepatitis B, C and D in Germany: A scoping review. PLOS ONE 2020; 15(3): e0229166 doi: 10.1371/journal.pone.0229166
|